Macozinone clinical trials
Also written PBTZ169.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses macozinone is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- PBTZ169
- 3
Studies by the year they started
5 studies that test it; most in 2016 (2)
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 2
Nearmedic Plus LLC (3) · Innovative Medicines for Tuberculosis (2)
Studies
Open first, then newest update. How each study uses macozinone is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PBTZ169 in Multiple DosingCompletedPhase 1Innovative Medicines for TuberculosisNCT03776500Written as PBTZ169
- Phase 1 Study of PBTZ169CompletedPhase 1Nearmedic Plus LLCNCT03036163Written as PBTZ169 - 40 mg
- Phase 2a Study of PBTZ169TerminatedPhase 2Nearmedic Plus LLCNCT03334734Written as PBTZ169
- Safety, Tolerability, Pharmacokinetics and Food Effects Study of PBTZ169CompletedPhase 1Nearmedic Plus LLCNCT04150224Written as PBTZ169 640 mg OD
- Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Ex-vivo Antitubercular Activity of PBTZ169 FormulationCompletedPhase 1Innovative Medicines for TuberculosisNCT03423030Written as PBTZ169 Formulation
Codes
What other systems call macozinone · ClinicalTrials.gg INT000108
- MeSH (NLM) C000592783macozinoneConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) A3M1353L40MACOZINONEConfirmed FDA, NLM
- NCI Thesaurus C174599MacozinoneOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000592783 | macozinone | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | A3M1353L40 | MACOZINONE | Confirmed FDA, NLM |
| NCI Thesaurus | C174599 | Macozinone | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.